Cargando…
Can Schlafen 11 Help to Stratify Ovarian Cancer Patients Treated with DNA-Damaging Agents?
SIMPLE SUMMARY: Anticancer agents causing DNA damage are widely used in the treatment of ovarian cancer; however, predictive biomarkers capable of optimizing the selection of patients with the best likelihood of a good response have not been defined yet. The newly discovered protein Schlafen 11 was...
Autores principales: | Bednarikova, Marketa, Hausnerova, Jitka, Ehrlichova, Lucie, Matulova, Kvetoslava, Gazarkova, Eliska, Minar, Lubos, Weinberger, Vit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139752/ https://www.ncbi.nlm.nih.gov/pubmed/35625957 http://dx.doi.org/10.3390/cancers14102353 |
Ejemplares similares
-
Tumor Characteristic Variations between Symptomatic and Asymptomatic Endometrial Cancer
por: Vinklerová, Petra, et al.
Publicado: (2021) -
Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?
por: Vinklerová, Petra, et al.
Publicado: (2021) -
New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers
por: Holcakova, Jitka, et al.
Publicado: (2021) -
A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers
por: Weinberger, Vit, et al.
Publicado: (2019) -
The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer
por: Bednarikova, Marketa, et al.
Publicado: (2021)